---
title: 'Vice President, Medical Affairs at Lexeo Therapeutics'
canonical: 'https://feeny.ai/job/vice-president-medical-affairs-lexeo-therapeutics-new-york-rfht2sa2jn1x'
type: 'job'
last_seen: '2026-09-14'
---

# Vice President, Medical Affairs at Lexeo Therapeutics

- **Company:** Lexeo Therapeutics
- **Location:** New York, NY
- **Compensation:** $300k–$350k
- **Employment:** full-time
- **Work type:** hybrid
- **Posted:** 2026-06-04
- **Last confirmed live:** 2026-09-14
- **Apply:** https://jobs.lever.co/lexeotx/91d651e7-d70f-483b-9e01-1ff5b1684bfe

## Job description

## Role Summary

The Vice President, Medical Affairs will provide enterprise-level leadership across Lexeo’s gene therapy program. Reporting to the Chief Medical Officer, this role will set the strategic direction for Medical Affairs, overseeing scientific communications, congress strategy, external expert engagement, medical information, medical evidence generation and medical education. This individual will serve as a senior cross-functional leader and strategic partner to Clinical Development, Regulatory, and Patient Advocacy teams. In this role, they will shape and scale the Medical Affairs function, build organizational capabilities, and drive external scientific leadership in support of Lexeo’s development and future commercialization objectives. The ideal candidate is a strategic, hands-on leader who thrives in a dynamic, high-growth environment and can influence across the organization and external stakeholders.

Primary Responsibilities

- Define and lead the global Medical Affairs strategy across Lexeo’s portfolio, ensuring alignment with development milestones and business objectives
- Build, mentor, and lead a high-performing Medical Affairs organization, including external partners and future in-house team members
- Own scientific communications strategy, including publications planning, congress strategy, medical education, and dissemination of clinical and disease-state insights
- Establish and oversee external engagement strategy with key opinion leaders, investigators, medical societies, and patient advocacy organizations
- Serve as the senior Medical Affairs representative in cross-functional governance, partnering with Clinical Development, Regulatory, Market Access, and Patient Advocacy leaders
- Guide medical input into clinical development plans, patient identification strategies, launch readiness planning, and evidence-generation priorities
- Oversee medical review processes and ensure high-quality, compliant externally facing scientific content and response materials
- Lead advisory board strategy and execution, translating stakeholder insights into actionable plans for development and commercialization
- Represent Lexeo externally at major scientific meetings, investigator forums, and executive-level partner interactions
- Drive the development of onboarding, scientific training, and internal medical education initiatives to elevate organizational disease-area expertise
- Lead medical evidence generation and align the same with company objectives

Required Skills and Qualifications

- Advanced degree in life sciences, medicine, or a related field required (MD, PharmD, PhD preferred) with 10+ years of industry experience
- Significant Medical Affairs leadership experience in biotechnology or pharmaceuticals, with demonstrated progression in scope and responsibility
- Deep expertise in scientific communications, external expert engagement, medical strategy, and cross-functional collaboration
- Experience building or scaling Medical Affairs capabilities in a growth-stage organization, especially on transitioning from clinical stage to commercialization, is strongly preferred
- Strong executive presence with excellent written and verbal communication skills and the ability to influence senior internal and external stakeholders
- Ability to operate strategically while remaining hands-on in a fast-paced, evolving environment
- Experience with real world datasets and studies
- A working knowledge of how to incorporate artificial intelligence and machine learning principles into medical affairs

## About Lexeo

Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact. Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home. Lexeo Therapeutics is an EEO employer committed to an exciting, diverse,  and enriching work environment.

## About Lexeo Therapeutics

## Company Overview
- **One-liner**: Lexeo Therapeutics is a clinical-stage genetic medicine company pioneering gene therapies to treat the root causes of inherited cardiovascular diseases and APOE4-associated Alzheimer’s disease.
- **Entity Type**: Public (NYSE: LXEO) – IPO in 2023
- **Headquarters**: New York, New York, United States (345 Park Avenue South, Floor 6)
- **Founded**: 2018
- **Founders**: Ronald Crystal, MD (Founder & Chief Scientific Adviser)

## Core Business
- **Primary industry/industries**: Biotechnology / Genetic Medicine / Gene Therapy
- **Target customers**: B2B (healthcare providers, clinical research institutions, patients via healthcare systems) – focus on larger-rare and prevalent cardiovascular indications with high unmet need.
- **Mission or purpose statement**: “Reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated” (from 10-K) – also “going beyond treating the symptoms of genetic disease by trying to stop its progress at its underlying cause” (from careers page).

## Products & Services
- **LX2006**: Gene therapy candidate for cardiomyopathy associated with Friedreich’s Ataxia (FA). Currently in Phase 1/2 SUNRISE-FA trial; positive interim data reported in 2025/2026. Plans to initiate a registrational study (SUNRISE-FA 2) in H1 2026.
- **LX2020**: Gene therapy candidate for arrhythmogenic cardiomyopathy (ACM) caused by PKP2 mutations. In Phase 1/2 HEROIC-PKP2 trial; positive interim data announced January 2026.
- **Preclinical pipeline**: Additional programs targeting hypertrophic cardiomyopathy, APOE4-associated Alzheimer’s disease, and other genetically defined conditions.

## Market Standing
- **Valuation/Market Cap**: $329.6 million (as of recent data from LinkedIn, 2026)
- **Key Metric**: Annual revenue of $654K (pre-commercial, clinical-stage); total funding not directly disclosed but backed by IPO and institutional investors.
- **Notable Investors/Partners**: Partnerships with Weill Cornell Medicine and University of California San Diego; institutional investors include those common in biotech IPOs (specific names not listed in provided sources).
- **Growth Signals**: 
  - Headcount grew 18.5% YoY to 81 employees (LinkedIn).
  - Positive interim clinical data for both lead programs.
  - FDA feedback expected Q2 2026 for registrational trial design.
  - Expanded pipeline into AI/Data Science for drug discovery (new Sr. Director role posted).

## Competitive Advantages
- **AAVrh10 vector technology**: High transduction efficiency in myocardial cells, lower toxicity potential, and low pre-existing immunity compared to other AAV serotypes.
- **Focus on larger-rare cardiovascular diseases**: Targeting conditions with high unmet need and no approved treatments, enabling a stepwise, capital-efficient development approach.
- **Strong academic partnerships**: Groundbreaking research from Weill Cornell and UCSD provides foundational science and credibility.
- **Full ownership**: Retains exclusive worldwide development and commercialization rights to all product candidates.

## Strategic Focus
- **Late-stage clinical advancement**: Pushing LX2006 and LX2020 toward registrational trials and potential BLA submission.
- **AI and data science integration**: Hiring a Senior Director of AI and Data Science to accelerate decision-making across discovery, development, and operations.
- **Expanding pipeline**: Leveraging early proof-of-concept data to address larger-rare and prevalent indications beyond current lead programs.
- **Manufacturing and CMC**: Scaling up AAV manufacturing processes using Sf9/baculovirus and HEK-based systems.

## Why Work Here
- **Culture**: “Passion to change the arc of medicine” – a mission-driven environment focused on transformative gene therapies.
- **Work model**: Hybrid – 2 days/week in the New York City office, 3 days remote (from careers page).
- **Compensation & benefits**:
  - Competitive salaries (e.g., Director/Sr. Director Clinical Development: $247,500 – $382,000/year)
  - Health, dental, vision, mental health benefits
  - 401(K) with company match, performance bonus, company equity
  - Unlimited PTO, paid holidays, paid parental leave
  - Commuter benefits, tech stipend, stocked kitchen, in-office lunch stipend
  - Life and disability insurance
- **Team**: Led by pioneers in gene therapy and rare disease drug development; small but growing company (81 employees) offering high impact and cross-functional ownership.
- **EEO**: Committed to an exciting, diverse, and enriching work environment.

## Sources
1. [sec.gov](https://www.sec.gov/Archives/edgar/data/1907108/000119312526193939/ars_10-k_2025.pdf) – Form 10-K for FY2025 (filed March 2026)
2. [linkedin.com](https://linkedin.com/company/lexeo-therapeutics) – LinkedIn company page (employees, revenue, market cap)
3. [lexeotx.com](https://www.lexeotx.com/careers/) – Careers page (benefits, culture, hybrid policy, job postings)
4. [jobs.lever.co](https://jobs.lever.co/lexeotx) – Lever job board (open positions)
5. [lexeotx.com](https://www.lexeotx.com/team/) – Leadership team page (founder, executives)

## Other roles at Lexeo Therapeutics

- [Senior Scientist, Process Development (AAV)](https://feeny.ai/job/senior-scientist-process-development-aav-lexeo-therapeutics-new-york-7apz9n3zedj0) — New York, NY
- [Associate Director, Quality Systems and Compliance](https://feeny.ai/job/associate-director-quality-systems-and-compliance-lexeo-therapeutics-new-york-ygjm53j4ddfr) — New York, NY
- [Director/Senior Director, Clinical Development](https://feeny.ai/job/director-senior-director-clinical-development-lexeo-therapeutics-new-york-vkywdkr3hqn8) — New York, NY
- [Senior Director, AI and Data Science (Drug Discovery and R&D Enablement)](https://feeny.ai/job/senior-director-ai-and-data-science-drug-discovery-and-r-d-enablement-lexeo-wazq9qsgbtag) — New York, NY
- [Vice President, Medical Affairs](https://feeny.ai/job/vice-president-medical-affairs-orca-bio-menlo-park-v3385y6p39b0) — Menlo Park, CA
- [Vice President, Medical Affairs](https://feeny.ai/job/vice-president-medical-affairs-alumis-south-san-francisco-wf29rz4etq59) — South San Francisco, CA